Related Experiment Videos
Maintenance therapy for low-grade lymphomas: has the time come?
Guillaume Cartron1, Philippe Solal-Céligny
1Service d'Hématologie Clinique, Centre Hospitalier Universitaire (CHU) de Montpellier, France. guillaume.cartron@med.univ-tours.fr
Current Opinion in Oncology
|September 1, 2007
Summary
Rituximab maintenance therapy significantly improves progression-free survival and response duration in indolent non-Hodgkin's lymphomas. It demonstrates a survival benefit in follicular lymphoma, supporting its use in relapsed cases.
Area of Science:
- Oncology
- Hematology
- Clinical Trials
Background:
- Rituximab (MabThera, Rituxan) maintenance therapy represents a significant advancement in managing low-grade non-Hodgkin's lymphomas.
- Indolent non-Hodgkin's lymphomas (iNHL) are a group of B-cell malignancies characterized by slow progression.
Purpose of the Study:
- To review the impact of rituximab maintenance treatment on outcomes in indolent non-Hodgkin's lymphomas.
- To evaluate the efficacy and safety of rituximab maintenance based on recent randomized trials.
Main Methods:
- Analysis of five recent randomized controlled trials involving rituximab maintenance in iNHL.
- Inclusion of patients with follicular lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma, primarily in relapse.
- Random assignment of responding patients to either observation or rituximab maintenance post-initial therapy.
Main Results:
- Rituximab maintenance significantly improved progression-free survival and response duration across studied iNHL subtypes.
- Overall survival was increased in two trials, indicating a long-term benefit.
- One trial showed superior progression-free survival with rituximab maintenance compared to retreatment at progression.
Conclusions:
- Rituximab maintenance therapy shows a clear survival benefit in patients with follicular lymphoma, justifying its recommendation for relapsed cases.
- Further research is necessary to establish efficacy in first-line settings and other histological subtypes, as well as to determine optimal dosing schedules.
- While severe adverse events were not prominent in trials, long-term toxicity data are limited, necessitating careful patient monitoring.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Secondary Lymphoid Organs
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...